Crewe Advisors LLC Lowers Stock Holdings in Stryker Co. (NYSE:SYK)

Crewe Advisors LLC reduced its stake in Stryker Co. (NYSE:SYK) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,040 shares of the medical technology company’s stock after selling 87 shares during the period. Crewe Advisors LLC’s holdings in Stryker were worth $374,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Czech National Bank increased its stake in Stryker by 8.1% in the 3rd quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock valued at $25,231,000 after buying an additional 5,235 shares during the period. Dynamic Advisor Solutions LLC grew its position in shares of Stryker by 2.3% in the third quarter. Dynamic Advisor Solutions LLC now owns 2,990 shares of the medical technology company’s stock valued at $1,080,000 after purchasing an additional 67 shares during the last quarter. Atomi Financial Group Inc. increased its position in Stryker by 2.3% during the third quarter. Atomi Financial Group Inc. now owns 2,091 shares of the medical technology company’s stock worth $755,000 after buying an additional 47 shares in the last quarter. Sugarloaf Wealth Management LLC raised its stake in Stryker by 32.7% in the 3rd quarter. Sugarloaf Wealth Management LLC now owns 446 shares of the medical technology company’s stock valued at $161,000 after purchasing an additional 110 shares during the last quarter. Finally, Reliant Investment Management LLC lifted its stake in shares of Stryker by 0.9% during the third quarter. Reliant Investment Management LLC now owns 15,200 shares of the medical technology company’s stock valued at $5,491,000 after buying an additional 138 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. UBS Group upped their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Citigroup raised their price target on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Finally, The Goldman Sachs Group raised their price target on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $419.37.

Stryker Price Performance

Shares of NYSE SYK opened at $399.01 on Thursday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $376.87 and its 200-day moving average is $364.00. The firm has a market cap of $152.11 billion, a P/E ratio of 51.42, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the firm posted $3.46 EPS. Equities research analysts predict that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.84%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.